We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Cardiomyopathy in obesity, insulin resistance and diabetes.
- Authors
Nakamura, Michinari; Sadoshima, Junichi
- Abstract
The prevalence of obesity, insulin resistance and diabetes is increasing rapidly. Most patients with these disorders have hypertriglyceridaemia and increased plasma levels of fatty acids, which are taken up and stored in lipid droplets in the heart. Intramyocardial lipids that exceed the capacity for storage and oxidation can be lipotoxic and induce non‐ischaemic and non‐hypertensive cardiomyopathy, termed diabetic or lipotoxic cardiomyopathy. The clinical features of diabetic cardiomyopathy are cardiac hypertrophy and diastolic dysfunction, which lead to heart failure, especially heart failure with preserved ejection fraction. Although the pathogenesis of the cardiomyopathy is multifactorial, diabetic dyslipidaemia and intramyocardial lipid accumulation are the key pathological features, triggering cellular signalling and modifications of proteins and lipids via generation of toxic metabolic intermediates. Most clinical studies have shown no beneficial effect of anti‐diabetic agents and statins on outcomes in heart failure patients without atherosclerotic diseases, indicating the importance of identifying underlying mechanisms and early interventions for diabetic cardiomyopathy. Here, we summarize the molecular mechanisms of diabetic cardiomyopathy, with a special emphasis on cardiac lipotoxicity, and discuss the role of peroxisome proliferator‐activated receptor α and dysregulated fatty acid metabolism as potential therapeutic targets.
- Subjects
INSULIN resistance; DIABETIC cardiomyopathy; CARDIAC hypertrophy; PEROXISOME proliferator-activated receptors; PATHOLOGY
- Publication
Journal of Physiology, 2020, Vol 598, Issue 14, p2977
- ISSN
0022-3751
- Publication type
Article
- DOI
10.1113/JP276747